Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Solid Biosciences Inc. (SLDB)

Solid Biosciences: Director Ilan Ganot moves from Class III to Class I board seat

Neutral Impact 1 of 5 leadership Written later

Solid Biosciences disclosed that director Ilan Ganot resigned from its Class III board seat and was appointed to a Class I seat effective April 10, 2026, to balance board class membership. The move carries no change to his compensation, and the company plans to ask stockholders to ratify the appointment at its 2026 annual meeting.

Key points

  • Ganot resigned from Class III and was appointed to Class I, effective 4:00 p.m. Eastern Time on April 10, 2026.
  • Class I term expires at the 2028 Annual Meeting of Stockholders; he will not stand for election in 2027.
  • No changes to Ganot's compensation and no compensation due from his resignation or appointment.
  • Board Class III reduced to three directors and Class I increased to three directors.

The filing

CompanySolid Biosciences Inc. (SLDB)
Form8-K, current report
Filed with the SECApr 10, 2026, 4:09 PM ET
Accession number0001193125-26-151259

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 10, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.